Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT05010096	Phase I	Copanlisib + Elimusertib	BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors	Withdrawn		0
NCT05327010	Phase II	Talazoparib + ZEN-3694	Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial	Recruiting	USA	0
NCT05687110	Phase I	Novobiocin	Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes	Recruiting	USA \| CAN	0
NCT02925234	Phase II	Niraparib Tepotinib Erdafitinib Ivosidenib Panitumumab Pemigatinib	The Drug Rediscovery Protocol (DRUP Trial) (DRUP)	Recruiting	NLD	0
NCT03047135	Phase II	Olaparib	Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis	Active, not recruiting	USA	0
NCT03840967	Phase II	Niraparib	A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma	Terminated	USA	0
NCT04983745	Phase II	Dostarlimab-gxly + Niraparib	Niraparib and Dostarlimab in HRD Solid Tumors (DIDO)	Recruiting	USA	0
NCT03992131	Phase Ib/II	Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan-hziy	A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR)	Terminated	USA	0
NCT05340413	Phase II	Olaparib	Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA)	Unknown status	ESP	0
NCT04779151	Phase II	Dostarlimab-gxly + Niraparib	Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO)	Terminated	FRA	0
NCT05188508	Phase II	Olaparib + Pembrolizumab + Temozolomide	Pembrolizumab, Olaparib, and Temozolomide for People with Glioma	Recruiting	USA	0
NCT04171700	Phase II	Rucaparib	A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR)	Terminated	USA	0
NCT06844383	Phase II	Enzalutamide + Talazoparib Talazoparib	A Study of Talazoparib with or Without Enzalutamide in People with Prostate Cancer Who Have Previously Received Abiraterone Acetate (TALENT)	Recruiting	USA	0
NCT02401347	Phase II	Talazoparib	Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors	Completed	USA	0
NCT04019327	Phase Ib/II	Talazoparib + Temozolomide	A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer	Active, not recruiting	USA	0
NCT05442749	Phase II	Niraparib	Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer (PARPi-PANC)	Withdrawn	FRA	0
NCT05174455	Phase II	Niraparib	Niraparib for the Treatment of Leiomyosarcoma	Withdrawn		0
NCT04053322	Phase II	Durvalumab + Fulvestrant + Olaparib	Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF)	Active, not recruiting	FRA	0
NCT04666740	Phase II	Olaparib + Pembrolizumab	A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy	Active, not recruiting	USA	0
NCT03344965	Phase II	Olaparib	Olaparib in Metastatic Breast Cancer	Active, not recruiting	USA	0
NCT04493060	Phase II	Dostarlimab-gxly + Niraparib	Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer	Completed	USA	0
NCT04253262	Phase Ib/II	Copanlisib + Rucaparib	A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer	Active, not recruiting	USA	0
NCT03233204	Phase II	Olaparib	Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)	Completed	USA	1
NCT05417594	Phase Ib/II	AZD9574 + Trastuzumab deruxtecan AZD9574 + Datopotamab deruxtecan AZD9574 AZD9574 + Temozolomide	Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)	Recruiting	USA \| SWE \| GBR \| ESP \| DEU \| AUS	1
NCT05700721	Phase II	Dostarlimab-gxly + Niraparib	Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)	Recruiting	USA	0
NCT04550494	Phase II	Talazoparib	Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations	Recruiting	USA	0
NCT03786796	Phase II	Olaparib	Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID)	Recruiting	USA	0
NCT05501548	Phase II	Olaparib	Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer	Terminated	USA	0
NCT04693468	Phase I	Axitinib + Talazoparib Crizotinib + Talazoparib Palbociclib + Talazoparib	Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial	Recruiting	USA	0
NCT04890613	Phase I	CX-5461	Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation	Recruiting	USA \| CAN	0
NCT04030559	Phase II	Niraparib	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	Active, not recruiting	USA	0
NCT03810105	Phase II	Durvalumab + Olaparib	A Study of Olaparib and Durvalumab in Prostate Cancer	Terminated	USA	0
NCT04276376	Phase II	Atezolizumab + Rucaparib	Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES)	Terminated	FRA	0
NCT05986071	Phase Ib/II	Fulvestrant + M1774	I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX)	Not yet recruiting	FRA	0
NCT04266912	Phase Ib/II	Avelumab + Berzosertib	Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors	Active, not recruiting	USA	0
NCT04821622	Phase III	Enzalutamide Enzalutamide + Talazoparib	Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC	Active, not recruiting	USA \| TUR \| SVK \| NOR \| NLD \| ITA \| HUN \| GBR \| FRA \| FIN \| ESP \| DEU \| CZE \| CAN \| BGR \| BEL \| AUS \| ARG	9
NCT05338346	Phase I	ATG-018	A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM)	Terminated	AUS	0
NCT04985721	Phase II	Pamiparib + Tislelizumab	A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD)	Unknown status	AUS	0
NCT06747845	Phase II	Fluorouracil + Irinotecan + Leucovorin Ipilimumab + Niraparib	Maintenance Niraparib Plus Ipilimumab in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy (ParpVax2)	Recruiting	USA	0
NCT04826341	Phase Ib/II	Berzosertib + Sacituzumab govitecan-hziy	A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors	Recruiting	USA	0
NCT05033756	Phase II	Olaparib + Pembrolizumab	Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO (COMPRENDO)	Active, not recruiting	DEU	0
NCT04336943	Phase II	Durvalumab + Olaparib	Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load	Terminated	USA	0

Profile Name	RAD51C inact mut
Gene Variant Detail	RAD51C inact mut (loss of function)
Relevant Treatment Approaches	Olaparib

Molecular Profile Detail

Contact

Filtering

Sorting